查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2085555

大便潛血試驗市場：2026-2032年全球市場預測（按檢測類型、檢測方法、檢體採集方法、應用和最終用戶分類）

Fecal Occult Testing Market by Test Type, Test Method, Sample Collection Method, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，大便潛血試驗市場規模將達到 14.7521 億美元，複合年成長率為 8.16%。

主要市場統計數據
基準年 2025 8.5167億美元
預計年份：2026年 9.1836億美元
預測年份 2032 1,475,210,000 美元
複合年成長率 (%) 8.16%

大便潛血試驗仍然是結直腸癌篩檢中一項基礎且非侵入性的方法，因為它可以在許多患者出現症狀之前檢測到糞便中的隱血。此方法包括傳統的癒創木脂糞便大便潛血試驗（gFOBT）、高靈敏度gFOBT和糞便免疫化學檢查（FIT）。由於FIT對人類血紅蛋白具有特異性、檢體採集簡便且與定量檢測流程相容，因此在機構篩檢計畫中越來越受歡迎。

公共衛生證據確鑿。世界衛生組織（WHO）國際癌症研究機構（IARC）透過2022年全球癌症監測報告（GLOBOCAN 2022）指出，全球每年新增大腸直腸癌病例超過190萬例，死亡人數超過90萬，是預防癌症負擔最重的疾病之一。美國預防服務工作小組（USPSTF）的篩檢指南建議45至75歲的成年人每年進行大腸直腸癌篩檢，篩檢方法包括經批准的糞便檢驗，例如FIT或高靈敏度gFOBT。這些循證建議持續推動對準確、便捷且擴充性的大便潛血試驗解決方案的需求。

大便潛血試驗領域的變革性變化

大便潛血試驗的模式正在從以診所為中心的機會性檢測轉向以人群為基礎的有組織的篩檢模式，旨在提高後續大腸鏡檢查的參與率、公平性和完成率。糞便腸道檢測（FIT）是促成這一轉變的關鍵因素，因為它可以透過郵寄方式進行檢測，可以大規模處理，並且可以整合到數位提醒系統中，從而減少了與侵入性篩檢相關的障礙。

人工智慧對大便潛血試驗的累積影響

人工智慧 (AI) 透過識別符合條件的患者、優先進行推廣活動、管理物流和結果以及提高後續追蹤依從性，為整個大便潛血試驗計畫帶來累積價值。 AI 驅動的分析可以分析電子健康記錄，識別符合篩檢的成年人，標記錯過檢測截止日期的患者，個性化推廣訊息，並預測未寄回的郵寄試劑盒，從而幫助填補醫療保健系統中存在的篩檢缺口。

全球大便潛血試驗的關鍵區域見解

北美在大便潛血試驗大便潛血試驗(FIT) 的推廣應用方面發揮了主導作用，這得益於其完善的預防性篩檢建議、結直腸癌篩檢的醫保覆蓋以及在綜合醫療保健網路中廣泛開展的郵寄式 FIT 宣傳活動。在美國，根據美國預防服務工作小組 (USPSTF) 的建議，篩檢年齡從 45 歲開始，這主導了當地的 FIT 需求；而加拿大各省的篩檢計畫也持續高度依賴 FIT 作為人群篩檢工具。

影響大便潛血試驗需求的關鍵群體特定見解

在主要經濟和政策集團中，七國集團（G7）擁有最完善的大便潛血試驗商業化環境，這得益於其高額的醫療費用支出、成熟的檢測實驗室以及正式的結直腸癌篩檢指南。歐盟則因其協調一致的公共衛生政策、跨境品質保證以及持續向基於糞便免疫化學檢測（FIT）的系統性篩檢過渡而備受矚目。

來自重點國家關於引入大便潛血試驗。

美國仍然是糞便隱血檢測最具影響力的市場之一，其國家指南支持基於糞便的結大便潛血試驗篩檢，品質指標推動篩檢完成，大規模醫療保健系統採用郵寄式糞便免疫化學檢測（FIT）來覆蓋目標人群。加拿大持續透過省級篩檢計畫推廣FIT的應用，而隨著癌症預防政策、公眾意識和診斷可近性的提高，墨西哥和巴西的FIT市場潛力也不斷擴大。

為大便潛血試驗。

產業領導者應優先考慮基於FIT（糞便免疫化學檢測）的產品系列，這些產品組合應兼具臨床準確性、便利的檢體採集、自動化處理和數位連接性。產品策略應強調檢驗的靈敏度和特異性、穩定的檢體處理、清晰的患者解釋以及與實驗室資訊系統、電子健康記錄和人群健康管理平台的無縫整合。

基於證據的市場分析調查方法

本執行摘要基於對檢驗來源的系統性審查，包括經過驗證的公共衛生指南、同行評審的臨床文獻、世衛組織/國際癌症研究機構 GLOBOCAN資訊來源、美國預防服務工作組 (USPSTF) 結直腸癌篩檢建議、美國癌症協會 (ACS) 指南、歐洲篩檢政策文件以及可用的國家計畫資料。

結論：大便潛血試驗的未來

大便潛血試驗 ) 因其大便潛血試驗侵入性、可大規模開展且獲得主要篩檢指南的支持，被認為是全球大腸直腸癌預防的關鍵要素。隨著醫療衛生系統向早期檢測和人群健康意識提升活動轉型，FIT 因其操作優勢和患者接受度，預計將在篩檢策略中繼續發揮核心作用。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章大便潛血試驗市場：依試驗類型分類

  • 採用癒創木脂法進行糞便大便潛血試驗
  • 糞便免疫化學檢查（FIT/iFOBT）
  • 免疫 FOB 的變異

第8章大便潛血試驗市場：依檢測方法分類

  • 定性
  • 定量方法

第9章大便潛血試驗市場：依檢體採集法分類

  • 檢查室基地
  • 照護端
  • 首頁收藏

第10章：大便潛血試驗

  • 診斷
    • 每日診斷
    • 根據症狀進行診斷
  • 篩檢
    • 大規模健康檢查
    • 機械篩檢

第11章大便潛血試驗市場：依最終用戶分類

  • 診所
  • 診斷中心
  • 醫院
    • 大型醫院
    • 中小型醫院

第12章大便潛血試驗市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章大便潛血試驗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章大便潛血試驗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Abbott Laboratories
  • Bio-Rad Laboratories, Inc.
  • Cardinal Health
  • Cenogenics Corporation
  • CTK Biotech, Inc.
  • Danaher Corporation
  • Diagnostic Solutions Laboratory, LLC
  • DiaSorin SpA
  • Eiken Chemical Co., Ltd.
  • Emes Software, LLC
  • Epitope Diagnostics Inc.
  • Geisinger Medical Laboratories
  • Genova Diagnostics Inc.
  • Helena Laboratories Corporation
  • Hologic Inc.
  • Lauriston Laboratories Ltd
  • Meridian Bioscience Inc.
  • Pinnacle BioLabs
  • Polymedco, LLC
  • QIAGEN NV
  • Quest Diagnostics
  • QuidelOrtho Corporation
  • ScheBo Biotech AG
  • Siemens Healthineers
Product Code: MRR-4348D129FB2A

The Fecal Occult Testing Market is projected to grow by USD 1,475.21 million at a CAGR of 8.16% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 851.67 million
Estimated Year [2026] USD 918.36 million
Forecast Year [2032] USD 1,475.21 million
CAGR (%) 8.16%

Fecal occult testing remains a foundational, noninvasive approach for colorectal cancer screening because it detects hidden blood in stool before many patients develop symptoms. The category includes traditional guaiac fecal occult blood tests (gFOBT), high-sensitivity gFOBT, and fecal immunochemical tests (FIT), with FIT increasingly preferred in organized screening programs due to its human hemoglobin specificity, simplified sampling, and compatibility with quantitative laboratory workflows.

The public health rationale is firmly established. The World Health Organization's International Agency for Research on Cancer reported through GLOBOCAN 2022 that colorectal cancer accounted for more than 1.9 million new cases and over 900,000 deaths worldwide, making it one of the most significant preventable cancer burdens. Screening guidance from the U.S. Preventive Services Task Force recommends colorectal cancer screening for adults aged 45 to 75, with annual FIT or high-sensitivity gFOBT among accepted stool-based options. These evidence-backed recommendations continue to support demand for accurate, accessible, and scalable fecal occult testing solutions.

Transformative Shifts in the Fecal Occult Testing Landscape

The fecal occult testing landscape is shifting from opportunistic, clinic-centered testing toward organized, population-based screening models designed to improve participation, equity, and follow-up colonoscopy completion. FIT has become a key enabler of this transition because it can be mailed, processed at scale, and integrated into digital reminder systems, reducing barriers associated with invasive first-line screening.

Healthcare systems are also raising expectations for test performance, traceability, and quality assurance. Laboratories and diagnostic manufacturers are responding with automated analyzers, barcoded collection devices, standardized cutoffs, and electronic reporting that support higher throughput and more consistent interpretation. At the same time, adoption is being shaped by earlier screening age recommendations, growing awareness of early-onset colorectal cancer, and payer emphasis on preventive care metrics.

Cumulative Impact of Artificial Intelligence on Fecal Occult Testing

Artificial intelligence is adding cumulative value across fecal occult testing programs by improving patient identification, outreach prioritization, logistics, result management, and follow-up adherence. AI-enabled analytics can mine electronic health records to identify screening-eligible adults, flag overdue patients, tailor outreach messages, and predict non-return of mailed kits, helping health systems close documented screening gaps.

AI also supports operational quality by forecasting kit demand, optimizing laboratory staffing, and monitoring abnormal result pathways to reduce delays between positive stool tests and diagnostic colonoscopy. While AI does not replace validated fecal occult blood detection chemistry or colonoscopy confirmation, its role in workflow orchestration is increasingly important. Responsible adoption requires transparent model validation, bias monitoring, cybersecurity controls, and compliance with applicable health data regulations such as HIPAA in the United States and GDPR in Europe.

Key Regional Insights Across Global Fecal Occult Testing

North America is a leading adoption environment for fecal occult testing due to mature preventive screening recommendations, insurance coverage for colorectal cancer screening, and widespread use of mailed FIT outreach in integrated delivery networks. The United States anchors regional demand through USPSTF-backed screening from age 45, while Canada's provincial programs continue to rely heavily on FIT as a population-level screening tool.

Europe benefits from structured public health programs and European Union recommendations that support organized colorectal cancer screening, with FIT increasingly replacing older guaiac-based approaches in many national programs. Asia-Pacific is expanding as China, Japan, South Korea, Australia, and India respond to rising colorectal cancer incidence, urbanization, and broader preventive health initiatives. Latin America is advancing through public cancer control programs and improving diagnostic access, led by countries such as Brazil and Mexico. The Middle East is strengthening preventive health strategies through national transformation agendas and investment in laboratory infrastructure, while Africa presents important unmet screening needs, with adoption influenced by awareness, reimbursement, workforce capacity, and colonoscopy access after positive tests.

Key Group Insights Shaping Fecal Occult Testing Demand

Among major economic and policy groups, the G7 represents the most established environment for fecal occult testing commercialization due to high healthcare spending, mature laboratories, and formal colorectal cancer screening guidance. The European Union is notable for coordinated public health policy, cross-country quality assurance, and continued movement toward organized FIT-based screening.

BRICS countries represent a large-volume opportunity because of expanding middle-class populations, rising cancer awareness, and increasing public-sector investment in diagnostics, although screening infrastructure differs widely across China, India, Brazil, Russia, and South Africa. ASEAN markets are gaining momentum through healthcare modernization, expanding primary care access, and public-private diagnostic partnerships, while GCC countries are investing in preventive health programs aligned with national health transformation strategies. NATO membership itself is not a healthcare procurement framework, but many NATO countries overlap with high-income screening markets where laboratory automation, data security, interoperability, and resilient supply chains influence purchasing decisions.

Key Country Insights for Fecal Occult Testing Adoption

The United States remains one of the most influential fecal occult testing markets because national guidelines support stool-based colorectal cancer screening, quality measures incentivize screening completion, and large health systems use mailed FIT to reach eligible populations. Canada continues to advance FIT through provincial screening programs, while Mexico and Brazil show growing potential as cancer prevention policies, public awareness, and diagnostic access improve.

In Europe, the United Kingdom, Germany, France, Italy, and Spain rely on organized screening policies and laboratory networks that support broader FIT utilization, while Russia presents demand tied to cancer control priorities and regional healthcare capacity. China's large eligible population, Japan's long-standing screening culture, South Korea's national screening infrastructure, Australia's National Bowel Cancer Screening Program, and India's expanding diagnostic sector make Asia-Pacific central to fecal occult testing adoption. These country-level dynamics show that adoption depends not only on test availability, but also on public awareness, sample return rates, laboratory automation, reimbursement pathways, and timely colonoscopy follow-up.

Actionable Recommendations for Fecal Occult Testing Leaders

Industry leaders should prioritize FIT-based portfolios that combine clinical accuracy, user-friendly sample collection, automated processing, and digital connectivity. Product strategies should emphasize validated sensitivity and specificity, stable sample handling, clear patient instructions, and seamless integration with laboratory information systems, electronic health records, and population health platforms.

Commercial teams should align with screening programs, payers, employers, and primary care networks to improve kit distribution and return rates. Manufacturers and service providers can differentiate by offering end-to-end solutions that include outreach analytics, multilingual patient education, logistics support, abnormal-result tracking, and quality dashboards. Leaders should also invest in regulatory readiness, cybersecurity, supply chain resilience, and evidence generation that demonstrates improved screening completion and reduced downstream colorectal cancer burden.

Research Methodology for Evidence-Based Market Analysis

This executive summary is based on a structured review of verified public health guidance, peer-reviewed clinical literature, and recognized institutional sources, including WHO/IARC GLOBOCAN data, U.S. Preventive Services Task Force colorectal cancer screening recommendations, American Cancer Society guidance, European screening policy documents, and national program materials where available.

The analysis evaluates fecal occult testing across technology type, screening workflow, regional adoption, policy environment, healthcare infrastructure, and digital transformation. Insights were synthesized through evidence triangulation, focusing on documented screening recommendations, cancer burden statistics, laboratory practice trends, and implementation factors that influence real-world adoption. No unsupported market-size estimates, market share statements, forecasts, or unverified claims are used.

Conclusion: The Future of Fecal Occult Testing

Fecal occult testing is positioned as a critical component of global colorectal cancer prevention because it is noninvasive, scalable, and supported by major screening guidelines. As healthcare systems move toward earlier detection and population-level outreach, FIT is expected to remain central to screening strategies due to its operational advantages and patient acceptability.

The next phase of adoption will be shaped by automation, digital engagement, AI-assisted workflow management, and stronger linkage between positive stool tests and diagnostic colonoscopy. Organizations that combine validated testing performance with accessible delivery models and data-driven program support will be best positioned to improve outcomes and strengthen long-term relevance in fecal occult testing.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Fecal Occult Testing Market, by Test Type

  • 7.1. Guaiac Fecal Occult Blood Test
  • 7.2. Fecal Immunochemical Test (FIT / iFOBT)
  • 7.3. Immuno-FOB Variants

8. Fecal Occult Testing Market, by Test Method

  • 8.1. Qualitative
  • 8.2. Quantitative

9. Fecal Occult Testing Market, by Sample Collection Method

  • 9.1. Laboratory-based
  • 9.2. Point-of-care
  • 9.3. Home Collection

10. Fecal Occult Testing Market, by Application

  • 10.1. Diagnostic
    • 10.1.1. Routine Diagnosis
    • 10.1.2. Symptom Based Diagnosis
  • 10.2. Screening
    • 10.2.1. Mass Screening
    • 10.2.2. Opportunistic Screening

11. Fecal Occult Testing Market, by End User

  • 11.1. Clinics
  • 11.2. Diagnostic Centers
  • 11.3. Hospitals
    • 11.3.1. Large Hospitals
    • 11.3.2. Small And Medium Hospitals

12. Fecal Occult Testing Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Fecal Occult Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Fecal Occult Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Abbott Laboratories
  • 16.2. Bio-Rad Laboratories, Inc.
  • 16.3. Cardinal Health
  • 16.4. Cenogenics Corporation
  • 16.5. CTK Biotech, Inc.
  • 16.6. Danaher Corporation
  • 16.7. Diagnostic Solutions Laboratory, LLC
  • 16.8. DiaSorin S.p.A.
  • 16.9. Eiken Chemical Co., Ltd.
  • 16.10. Emes Software, LLC
  • 16.11. Epitope Diagnostics Inc.
  • 16.12. Geisinger Medical Laboratories
  • 16.13. Genova Diagnostics Inc.
  • 16.14. Helena Laboratories Corporation
  • 16.15. Hologic Inc.
  • 16.16. Lauriston Laboratories Ltd
  • 16.17. Meridian Bioscience Inc.
  • 16.18. Pinnacle BioLabs
  • 16.19. Polymedco, LLC
  • 16.20. QIAGEN N.V.
  • 16.21. Quest Diagnostics
  • 16.22. QuidelOrtho Corporation
  • 16.23. ScheBo Biotech AG
  • 16.24. Siemens Healthineers

LIST OF FIGURES

  • FIGURE 1. GLOBAL FECAL OCCULT TESTING MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL FECAL OCCULT TESTING MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL FECAL OCCULT TESTING MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL FECAL OCCULT TESTING MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL FECAL OCCULT TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL FECAL OCCULT TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL FECAL OCCULT TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL FECAL OCCULT TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL FECAL OCCULT TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FECAL OCCULT TESTING MARKET SIZE, BY TEST METHOD, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL FECAL OCCULT TESTING MARKET SIZE, BY TEST METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL FECAL OCCULT TESTING MARKET SIZE, BY SAMPLE COLLECTION METHOD, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL FECAL OCCULT TESTING MARKET SIZE, BY SAMPLE COLLECTION METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL FECAL OCCULT TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL FECAL OCCULT TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL FECAL OCCULT TESTING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL FECAL OCCULT TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL FECAL OCCULT TESTING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL FECAL OCCULT TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL FECAL OCCULT TESTING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL FECAL OCCULT TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL FECAL OCCULT TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL FECAL OCCULT TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL FECAL OCCULT TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL FECAL OCCULT TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GUAIAC FECAL OCCULT BLOOD TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GUAIAC FECAL OCCULT BLOOD TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GUAIAC FECAL OCCULT BLOOD TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL FECAL IMMUNOCHEMICAL TEST (FIT / IFOBT) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL FECAL IMMUNOCHEMICAL TEST (FIT / IFOBT) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL FECAL IMMUNOCHEMICAL TEST (FIT / IFOBT) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNO-FOB VARIANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNO-FOB VARIANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNO-FOB VARIANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL FECAL OCCULT TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL QUALITATIVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL QUALITATIVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL QUALITATIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL QUANTITATIVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL QUANTITATIVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL QUANTITATIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL FECAL OCCULT TESTING MARKET SIZE, BY SAMPLE COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LABORATORY-BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LABORATORY-BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LABORATORY-BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL POINT-OF-CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL POINT-OF-CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL POINT-OF-CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HOME COLLECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HOME COLLECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HOME COLLECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL FECAL OCCULT TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DIAGNOSTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ROUTINE DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ROUTINE DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ROUTINE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SYMPTOM BASED DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SYMPTOM BASED DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SYMPTOM BASED DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MASS SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MASS SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MASS SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL OPPORTUNISTIC SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL OPPORTUNISTIC SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL OPPORTUNISTIC SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL FECAL OCCULT TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LARGE HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LARGE HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LARGE HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SMALL AND MEDIUM HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SMALL AND MEDIUM HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SMALL AND MEDIUM HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL FECAL OCCULT TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC FECAL OCCULT TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC FECAL OCCULT TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC FECAL OCCULT TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC FECAL OCCULT TESTING MARKET SIZE, BY SAMPLE COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC FECAL OCCULT TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC FECAL OCCULT TESTING MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC FECAL OCCULT TESTING MARKET SIZE, BY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC FECAL OCCULT TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC FECAL OCCULT TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA FECAL OCCULT TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA FECAL OCCULT TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA FECAL OCCULT TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA FECAL OCCULT TESTING MARKET SIZE, BY SAMPLE COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA FECAL OCCULT TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA FECAL OCCULT TESTING MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA FECAL OCCULT TESTING MARKET SIZE, BY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA FECAL OCCULT TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA FECAL OCCULT TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA FECAL OCCULT TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA FECAL OCCULT TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA FECAL OCCULT TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA FECAL OCCULT TESTING MARKET SIZE, BY SAMPLE COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA FECAL OCCULT TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA FECAL OCCULT TESTING MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA FECAL OCCULT TESTING MARKET SIZE, BY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA FECAL OCCULT TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA FECAL OCCULT TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE FECAL OCCULT TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE FECAL OCCULT TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE FECAL OCCULT TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE FECAL OCCULT TESTING MARKET SIZE, BY SAMPLE COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE FECAL OCCULT TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE FECAL OCCULT TESTING MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE FECAL OCCULT TESTING MARKET SIZE, BY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE FECAL OCCULT TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE FECAL OCCULT TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST FECAL OCCULT TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST FECAL OCCULT TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST FECAL OCCULT TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST FECAL OCCULT TESTING MARKET SIZE, BY SAMPLE COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST FECAL OCCULT TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST FECAL OCCULT TESTING MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST FECAL OCCULT TESTING MARKET SIZE, BY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST FECAL OCCULT TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST FECAL OCCULT TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA FECAL OCCULT TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA FECAL OCCULT TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA FECAL OCCULT TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA FECAL OCCULT TESTING MARKET SIZE, BY SAMPLE COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA FECAL OCCULT TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA FECAL OCCULT TESTING MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA FECAL OCCULT TESTING MARKET SIZE, BY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA FECAL OCCULT TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA FECAL OCCULT TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL FECAL OCCULT TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN FECAL OCCULT TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN FECAL OCCULT TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN FECAL OCCULT TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN FECAL OCCULT TESTING MARKET SIZE, BY SAMPLE COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN FECAL OCCULT TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN FECAL OCCULT TESTING MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN FECAL OCCULT TESTING MARKET SIZE, BY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN FECAL OCCULT TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN FECAL OCCULT TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 129. GCC FECAL OCCULT TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 130. GCC FECAL OCCULT TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. GCC FECAL OCCULT TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 132. GCC FECAL OCCULT TESTING MARKET SIZE, BY SAMPLE COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 133. GCC FECAL OCCULT TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. GCC FECAL OCCULT TESTING MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 135. GCC FECAL OCCULT TESTING MARKET SIZE, BY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 136. GCC FECAL OCCULT TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. GCC FECAL OCCULT TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION FECAL OCCULT TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION FECAL OCCULT TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION FECAL OCCULT TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION FECAL OCCULT TESTING MARKET SIZE, BY SAMPLE COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION FECAL OCCULT TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION FECAL OCCULT TESTING MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION FECAL OCCULT TESTING MARKET SIZE, BY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION FECAL OCCULT TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION FECAL OCCULT TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS FECAL OCCULT TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS FECAL OCCULT TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS FECAL OCCULT TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS FECAL OCCULT TESTING MARKET SIZE, BY SAMPLE COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS FECAL OCCULT TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS FECAL OCCULT TESTING MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS FECAL OCCULT TESTING MARKET SIZE, BY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS FECAL OCCULT TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS FECAL OCCULT TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 156. G7 FECAL OCCULT TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 157. G7 FECAL OCCULT TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. G7 FECAL OCCULT TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 159. G7 FECAL OCCULT TESTING MARKET SIZE, BY SAMPLE COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 160. G7 FECAL OCCULT TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. G7 FECAL OCCULT TESTING MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 162. G7 FECAL OCCULT TESTING MARKET SIZE, BY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 163. G7 FECAL OCCULT TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. G7 FECAL OCCULT TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 165. NATO FECAL OCCULT TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 166. NATO FECAL OCCULT TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. NATO FECAL OCCULT TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 168. NATO FECAL OCCULT TESTING MARKET SIZE, BY SAMPLE COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 169. NATO FECAL OCCULT TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. NATO FECAL OCCULT TESTING MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 171. NATO FECAL OCCULT TESTING MARKET SIZE, BY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 172. NATO FECAL OCCULT TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. NATO FECAL OCCULT TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL FECAL OCCULT TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES FECAL OCCULT TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES FECAL OCCULT TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES FECAL OCCULT TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES FECAL OCCULT TESTING MARKET SIZE, BY SAMPLE COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES FECAL OCCULT TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES FECAL OCCULT TESTING MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES FECAL OCCULT TESTING MARKET SIZE, BY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES FECAL OCCULT TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES FECAL OCCULT TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 184. CANADA FECAL OCCULT TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. CANADA FECAL OCCULT TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. CANADA FECAL OCCULT TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 187. CANADA FECAL OCCULT TESTING MARKET SIZE, BY SAMPLE COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 188. CANADA FECAL OCCULT TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. CANADA FECAL OCCULT TESTING MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 190. CANADA FECAL OCCULT TESTING MARKET SIZE, BY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 191. CANADA FECAL OCCULT TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. CANADA FECAL OCCULT TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 193. MEXICO FECAL OCCULT TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. MEXICO FECAL OCCULT TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. MEXICO FECAL OCCULT TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 196. MEXICO FECAL OCCULT TESTING MARKET SIZE, BY SAMPLE COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 197. MEXICO FECAL OCCULT TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 198. MEXICO FECAL OCCULT TESTING MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 199. MEXICO FECAL OCCULT TESTING MARKET SIZE, BY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 200. MEXICO FECAL OCCULT TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. MEXICO FECAL OCCULT TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 202. BRAZIL FECAL OCCULT TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. BRAZIL FECAL OCCULT TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. BRAZIL FECAL OCCULT TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 205. BRAZIL FECAL OCCULT TESTING MARKET SIZE, BY SAMPLE COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 206. BRAZIL FECAL OCCULT TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 207. BRAZIL FECAL OCCULT TESTING MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 208. BRAZIL FECAL OCCULT TESTING MARKET SIZE, BY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 209. BRAZIL FECAL OCCULT TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. BRAZIL FECAL OCCULT TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED KINGDOM FECAL OCCULT TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED KINGDOM FECAL OCCULT TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED KINGDOM FECAL OCCULT TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED KINGDOM FECAL OCCULT TESTING MARKET SIZE, BY SAMPLE COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED KINGDOM FECAL OCCULT TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED KINGDOM FECAL OCCULT TESTING MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED KINGDOM FECAL OCCULT TESTING MARKET SIZE, BY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED KINGDOM FECAL OCCULT TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED KINGDOM FECAL OCCULT TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 220. GERMANY FECAL OCCULT TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. GERMANY FECAL OCCULT TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. GERMANY FECAL OCCULT TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 223. GERMANY FECAL OCCULT TESTING MARKET SIZE, BY SAMPLE COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 224. GERMANY FECAL OCCULT TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. GERMANY FECAL OCCULT TESTING MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 226. GERMANY FECAL OCCULT TESTING MARKET SIZE, BY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 227. GERMANY FECAL OCCULT TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. GERMANY FECAL OCCULT TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 229. FRANCE FECAL OCCULT TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. FRANCE FECAL OCCULT TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. FRANCE FECAL OCCULT TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 232. FRANCE FECAL OCCULT TESTING MARKET SIZE, BY SAMPLE COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 233. FRANCE FECAL OCCULT TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 234. FRANCE FECAL OCCULT TESTING MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 235. FRANCE FECAL OCCULT TESTING MARKET SIZE, BY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 236. FRANCE FECAL OCCULT TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. FRANCE FECAL OCCULT TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 238. RUSSIA FECAL OCCULT TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. RUSSIA FECAL OCCULT TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. RUSSIA FECAL OCCULT TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 241. RUSSIA FECAL OCCULT TESTING MARKET SIZE, BY SAMPLE COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 242. RUSSIA FECAL OCCULT TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 243. RUSSIA FECAL OCCULT TESTING MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 244. RUSSIA FECAL OCCULT TESTING MARKET SIZE, BY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 245. RUSSIA FECAL OCCULT TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. RUSSIA FECAL OCCULT TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 247. ITALY FECAL OCCULT TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 248. ITALY FECAL OCCULT TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. ITALY FECAL OCCULT TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 250. ITALY FECAL OCCULT TESTING MARKET SIZE, BY SAMPLE COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 251. ITALY FECAL OCCULT TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 252. ITALY FECAL OCCULT TESTING MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 253. ITALY FECAL OCCULT TESTING MARKET SIZE, BY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 254. ITALY FECAL OCCULT TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. ITALY FECAL OCCULT TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 256. SPAIN FECAL OCCULT TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. SPAIN FECAL OCCULT TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. SPAIN FECAL OCCULT TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 259. SPAIN FECAL OCCULT TESTING MARKET SIZE, BY SAMPLE COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 260. SPAIN FECAL OCCULT TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 261. SPAIN FECAL OCCULT TESTING MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 262. SPAIN FECAL OCCULT TESTING MARKET SIZE, BY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 263. SPAIN FECAL OCCULT TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. SPAIN FECAL OCCULT TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA FECAL OCCULT TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA FECAL OCCULT TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA FECAL OCCULT TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA FECAL OCCULT TESTING MARKET SIZE, BY SAMPLE COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA FECAL OCCULT TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA FECAL OCCULT TESTING MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA FECAL OCCULT TESTING MARKET SIZE, BY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA FECAL OCCULT TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA FECAL OCCULT TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 274. INDIA FECAL OCCULT TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. INDIA FECAL OCCULT TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. INDIA FECAL OCCULT TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 277. INDIA FECAL OCCULT TESTING MARKET SIZE, BY SAMPLE COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 278. INDIA FECAL OCCULT TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 279. INDIA FECAL OCCULT TESTING MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 280. INDIA FECAL OCCULT TESTING MARKET SIZE, BY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 281. INDIA FECAL OCCULT TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. INDIA FECAL OCCULT TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 283. JAPAN FECAL OCCULT TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 284. JAPAN FECAL OCCULT TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. JAPAN FECAL OCCULT TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 286. JAPAN FECAL OCCULT TESTING MARKET SIZE, BY SAMPLE COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 287. JAPAN FECAL OCCULT TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 288. JAPAN FECAL OCCULT TESTING MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 289. JAPAN FECAL OCCULT TESTING MARKET SIZE, BY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 290. JAPAN FECAL OCCULT TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 291. JAPAN FECAL OCCULT TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 292. AUSTRALIA FECAL OCCULT TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 293. AUSTRALIA FECAL OCCULT TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. AUSTRALIA FECAL OCCULT TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 295. AUSTRALIA FECAL OCCULT TESTING MARKET SIZE, BY SAMPLE COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 296. AUSTRALIA FECAL OCCULT TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 297. AUSTRALIA FECAL OCCULT TESTING MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 298. AUSTRALIA FECAL OCCULT TESTING MARKET SIZE, BY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 299. AUSTRALIA FECAL OCCULT TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 300. AUSTRALIA FECAL OCCULT TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 301. SOUTH KOREA FECAL OCCULT TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 302. SOUTH KOREA FECAL OCCULT TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. SOUTH KOREA FECAL OCCULT TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 304. SOUTH KOREA FECAL OCCULT TESTING MARKET SIZE, BY SAMPLE COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 305. SOUTH KOREA FECAL OCCULT TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 306. SOUTH KOREA FECAL OCCULT TESTING MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 307. SOUTH KOREA FECAL OCCULT TESTING MARKET SIZE, BY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 308. SOUTH KOREA FECAL OCCULT TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 309. SOUTH KOREA FECAL OCCULT TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)